Edition:
India

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

6.65USD
1:30am IST
Change (% chg)

$-0.35 (-5.00%)
Prev Close
$7.00
Open
$6.95
Day's High
$6.95
Day's Low
$6.60
Volume
365,881
Avg. Vol
676,285
52-wk High
$10.65
52-wk Low
$1.55

Select another date:

Fri, May 11 2018

BRIEF-Sorrento Therapeutics Files For Resale Of Up To 1.38 Mln Shares Of Common Stock By The Selling Stockholders

* SORRENTO THERAPEUTICS INC FILES FOR RESALE OF UP TO 1.38 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2IdNCY0) Further company coverage:

BRIEF-Sorrento Therapeutics Files For Resale Of Up To 34.16 Mln Shares Of Common Stock By Selling Stockholders

* SORRENTO THERAPEUTICS INC FILES FOR RESALE OF UP TO 34.16 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [https://bit.ly/2rzywFX] Further company coverage:

BRIEF-Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing

* SORRENTO THERAPEUTICS ANNOUNCES UNSECURED $120.5M CONVERTIBLE NOTE FINANCING

BRIEF-Sorrento Therapeutics Files ‍Prospectus Related To Offering

* SORRENTO THERAPEUTICS INC FILES ‍PROSPECTUS RELATED TO OFFERING OF UP TO 1.4 MILLION SHARES CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2IFWs1n) Further company coverage:

BRIEF-Sorrento Therapeutics Files ‍Prospectus Related To Offering

* SORRENTO THERAPEUTICS INC FILES ‍PROSPECTUS RELATED TO OFFERING OF UP TO 34.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2pwUPvb) Further company coverage:

BRIEF-Sorrento Therapeutics Welcomes Jiong Shao As Chief Financial Officer

* SORRENTO THERAPEUTICS WELCOMES JIONG SHAO AS CHIEF FINANCIAL OFFICER AND REAFFIRMS INTENT TO SEEK NASDAQ/HKSE DUAL LISTING IN 2018

BRIEF-Sorrento Says Its CAR-T Cell Therapy Showed Therapeutic Activity In Stage IV Pancreas Cancer In Early Stage Trial

* SORRENTO THERAPEUTICS AUTOLOGOUS ANTI-CEA CAR-T CELL THERAPY FOR LIVER METASTASES DEMONSTRATES THERAPEUTIC ACTIVITY IN STAGE IV PANCREAS CANCER IN A PHASE 1B HITM-SURE TRIAL (NCT02850536) Source text for Eikon: Further company coverage:

FDA approves Sorrento's non-opioid painkiller patch, shares jump

Sorrento Therapeutics Inc said on Wednesday the U.S. Food and Drug Administration has approved ZTlido, its non-opioid painkiller patch for nerve pain related to shingles, which it plans to launch later this year.

UPDATE 2-FDA approves Sorrento's non-opioid painkiller patch, shares jump

* To compete with Endo's Lidoderm, generics (Adds background, company and analyst comments)

BRIEF-Sorrento Therapeutics' Unit Receives FDA Approval For Non-Opioid Ztlido

* SORRENTO THERAPEUTICS SUBSIDIARY, SCILEX, RECEIVES US FDA APPROVAL FOR NON-OPIOID ZTLIDO™ (LIDOCAINE TOPICAL SYSTEM) 1.8% FOR PHN PAIN

Select another date: